skin cancer Archive — Page 1 of 4
-
June 29, 2023
Study identifies key regulator of melanoma development
Vanderbilt investigators have revealed the mechanisms by which the chemokine receptor CXCR2, is associated with melanoma tumor formation and growth — a discovery that supports the continued development of drugs that inhibit the receptor’s activity. -
April 26, 2023
Good Save
-
August 11, 2022
Couple’s gift helps support immunotherapy research
Luke and Susan Simons have endowed a new directorship that will support research so that more people can benefit from immunotherapies. -
February 24, 2022
Melanoma treatment response
Targeting the interaction between melanoma and immune cells could improve responses to targeted cancer therapies, Vanderbilt researchers found. -
September 30, 2021
Prevention Progress
-
September 2, 2021
Using billing codes to count cancers
The billing codes in electronic health records are useful for counting skin cancers over time — an important metric for cancer risk assessment and prevention. -
July 1, 2021
Preclinical study supports rigosertib as booster to immunotherapy treatment for melanoma
A team of Vanderbilt researchers have shown in a preclinical study that the investigational drug rigosertib could be a potential booster treatment to elicit response to immunotherapies among melanoma patients.